Cabotib 40 Tablet
By Cabotib
Rx
30 Tablet in a Bottle

Composition
Cabozantinib(40mg)

Manufacturer - Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai – 400 026.

Expires on or after
July, 2025

liver
When using Cabotib 40 Tablet, you need to be careful if you have liver disease. It may be necessary to adjust the dosage of Cabotib 40 Tablet, so be sure to consult your doctor. If you have a history of liver issues, make sure to inform your doctor before starting this medication. Cazanat 40Mg Tab 30'S has the potential to cause liver damage when used with nivolumab, so patients with moderate liver problems should take this medicine cautiously. Your doctor might recommend liver function tests to keep an eye on how your liver is doing during the treatment.

kidney
For patients with kidney disease, Cabotib 40 Tablet is safe to use without requiring a dose adjustment. However, inform your doctor if you have a history of kidney issues, as they may adjust the dosage or recommend a different medicine.

alcohol
Avoid consuming alcohol while taking Cabotib 40 Tablet as it may lead to serious side effects. Consult your doctor about drinking alcohol while on this medication.

driving
Caution is advised while driving if you have been taking Cabotib 40 Tablet. It is unknown if this medication affects driving ability. Do not drive if you experience symptoms like dizziness or visual issues that may impair your focus and reaction time. Avoid driving until you are certain you can do so safely on this medication. It is better to consult your doctor. Refrain from driving if you have symptoms impairing focus and reaction time when using Cabotib 40 Tablet.

pregnancy
Cabotib 40 Tablet is not safe to use during pregnancy. Studies in animals suggest potential harm to the developing baby. Your doctor will assess the risks and benefits before prescribing. Please consult your doctor.

breastfeeding
During breastfeeding, it is advised to avoid using Cabotib 40 Tablet as it might pass into breastmilk and harm the baby. It is important not to breastfeed while taking this medication and for at least four months after the last dose.
Habit Forming | No |
Chemical Class | Diarylethers |
Therapeutic Class | - |
Action Class | Tyrosine kinase inhibitors |
₹8600
Inclusive of all taxes
Content verified by

Dr. Abdullah Khan
MBBS - General Medicine
Last update on 01-Oct-2024